GlassScriptPhysician profile
Timothy C Paden
NPI 1992761555
$869.02
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $111 · 2021: $94.54 · 2022: $238 · 2023: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $147.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $207.24 | 2019-2022 | |
| Amgen INC. | $136.20 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $112.69 | 2020-2022 | |
| Glaxosmithkline, LLC. | $82.65 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $66.33 | 2019-2023 | Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $55.51 | 2022 | |
| Medtronic, INC. | $52.26 | 2021 | |
| Novo Nordisk INC | $42.21 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.97 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $18.88 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $18.28 | 2023 | Austedo Xr |
| Ultragenyx Pharmaceutical INC. | $16.78 | 2023 | |
| Merck Sharp & Dohme LLC | $16.18 | 2022 | |
| Sumitomo Pharma America, INC. | $12.84 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Paden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.